Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR

By Josh Beckerman Ensysce Biosciences shares rose 39% Tuesday as the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its...

Related Keywords

Josh Beckerman ,Ensysce Biosciences ,Drug Administration ,Breakthrough Therapy Designation ,Article Normal ,Pharmaceuticals ,Healthcare Life Sciences ,Prescription Drugs ,Financial Performance ,Share Price Movement Disruptions ,Corporate Industrial News ,Drug Substance Use Abuse ,Political General News ,Society Community ,Heroin Illegal Opioid Use Abuse ,Social Issues ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Mensc ,Share Price Movement ,Disruptions ,Corporate ,Industrial News ,Drug ,Substance Use ,Abuse ,Political ,General News ,Society ,Community ,Heroin ,Illegal Opioid Use ,Healthcare ,Life Sciences ,